BS
REGN icon

Boenning & Scattergood’s Regeneron Pharmaceuticals REGN Stock Holding History

Boenning & Scattergood’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$307K Hold
440
– – 0.05% 318
2022
Q3 		$303K Hold
440
– – 0.06% 295
2022
Q2 		$260K Hold
440
– – 0.05% 319
2022
Q1 		$307K Buy
+440
New +$278K 0.05% 318
2020
Q4 		– Sell
-544
Closed -$305K – 347
2020
Q3 		$305K Buy
+544
New +$330K 0.07% 252

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boenning & Scattergood's REGN Position: Q4 2022 in Review

Boenning & Scattergood held its Regeneron Pharmaceuticals (REGN) position steady in Q4 2022 at 440 shares worth $307K. The position accounts for 0.05% of the portfolio, ranked #318.

Boenning & Scattergood first reported a position in REGN in Q3 2020 and has held it in 5 quarters since. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Boenning & Scattergood held 440 shares of Regeneron Pharmaceuticals worth $307K as of Q4 2022.
  • Boenning & Scattergood left its Regeneron Pharmaceuticals share count unchanged in Q4 2022.
  • Regeneron Pharmaceuticals made up 0.05% of Boenning & Scattergood's portfolio in Q4 2022, its #318 holding.
  • Boenning & Scattergood first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 5 quarters since.
  • 1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Boenning & Scattergood's 13F filing for Q4 2022, filed 26 Jan 2023.